Explorna Therapeutics sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2019-05-16
Share capital
9,100.00 PLN
Activity description

Explorna Therapeutics is a company that develops mRNA as a therapeutic platform and offers novel cap analogs for mRNA vaccines and therapeutics. They provide technology and therapeutic programs to pharmaceutical partners, aiming to advance disease treatment and prevention.

Registered address
ul. Żwirki I Wigury 93/2157, 02-089 Warszawa, Poland
Email

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed.

  • 2025not filed
  • 202427/06/2025
  • 202315/05/2024
  • 202223/06/2023
  • 202127/06/2022
  • 202001/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Top 28%
Voivodeship · Mazowieckie57,047 / 142,204
Top 40%
Country · Poland207,676 / 496,474
Top 42%

Results vs industry

Revenue
This companyUSD 304.66kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -2.53mMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 2.83mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 6.01mMedianUSD 134.71kAverageUSD 3.04m

Offer

Websites

  • explorna.comHomepage - ExploRNA
    WooCommerce 11.2WordPress 7.1Google Tag ManagerYoast SEOWPMLLiteSpeed

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2021.

MarkNumberClassesStatusProtected until
EXPLORNA (word)Z.5233485, 42, 44Protected Jan 20, 2031
MarkProtected until
EXPLORNA (word)Jan 20, 2031

Authorized Representatives

Jakub Adam Gołąb age 54 – Management Board Member
Mateusz Gołąb age 53 – Management Board Member
Jacek Jemielity age 53 – President of the Management Board
Joanna Kowalska – Management Board Member
Tomasz Piec age 57 – Management Board Member

Manner of representation

The right to represent the company is vested in two members of the management board acting jointly, or in a member of the management board acting jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
42$567.2623.0769%
Ms Galleon Gmbh
87$1,175.0447.8022%
Joanna Kowalska
18$243.119.8901%
Marek Rafał Baranowski
9$121.564.9451%
9$121.564.9451%
8$108.054.3956%
Dominika Anna Nowis
5$67.532.7473%
4$54.022.1978%

Beneficial owners

Person

Capital group

The company belongs to the MS Galleon GmbH (Austria) group, which is its direct owner. The group has 15 companies, 5 of them abroad.

NameCountry
BarlinekPoland
Barlinek InwestycjePoland
CersanitPoland
EkovoltisPoland
FTF ColumbusPoland

Bank accounts

Registered as a VAT taxpayer on 2020-04-22.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

4 public aid cases recorded, with a total value of $5,784,945.

PurposeGross amount
Aid for research and development projects: industrial research
$804.2K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$3,846
Aid for research and development projects: industrial research
$3.9M

European Funds

ProjectEU co-financing
Development of experimental anticancer immunotherapy based on therapeutic mRNAs modified with innovative next-generation cap analogues
$5M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Biotechna S.A.
Captor Therapeutics S.A.
Precisionlife Poland sp. z o.o.
Famicordtx S.A.
Camino Science sp. z o.o.
Pharmena S.A.
Vaxican sp. z o.o.
Medicofarma Biotech S.A.
Multiqure S.A.
WPD Pharmaceuticals S.A.

Change history

DateEvent
2023-11-28Share capital increase
2023-03-01Address change
2022-07-20Share capital increase
2022-02-07Share capital increase
2021-06-10Share capital increase

FAQ

Last updated: 2026-04-13